Cardurion Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cardurion Pharmaceuticals Inc.
The planned all-stock transaction will enable Enliven to take over Imara’s Nasdaq listing with cash runway into 2026. Imara shareholders get contingent value rights tied to sold-off top candidate tovinontrine.
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.
Imara has raised $63m to pursue its PDE9 inhibitor for sickle cell disease, and hopes to broaden the Phase II drug candidate into related blood disorders such as beta thalassemia.
Senior executives are to depart Gilead Sciences, Bristol-Myers Squibb and Amgen, while C-suite and board hires have been reported at Sirnaomics, Pandion, Purdue Pharma, Cardurion and OncoSec.